NuCana plc Sponsored ADR Aktie News

Die endgültigen Daten aus der Phase‑2‑Erweiterungsstudie von NUC-7738 bleiben für 2026 im Zeitplan Zusätzliche Indikationen und Kombinationsstrategien für NUC-7738 werden vorangetrieben Erwarteter Cash-Runway soll bis mindestens 2029 reichen EDINBURGH, United Kingdom, 13. Aug. 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) ("NuCana" oder "das Unternehmen") gab heute die Finanzergebnisse für...

EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and wa...

Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial resul...